HK1166786A1 - Tofa analogs useful in treating dermatological disorders or conditions - Google Patents

Tofa analogs useful in treating dermatological disorders or conditions

Info

Publication number
HK1166786A1
HK1166786A1 HK12107397.0A HK12107397A HK1166786A1 HK 1166786 A1 HK1166786 A1 HK 1166786A1 HK 12107397 A HK12107397 A HK 12107397A HK 1166786 A1 HK1166786 A1 HK 1166786A1
Authority
HK
Hong Kong
Prior art keywords
conditions
dermatological disorders
analogs useful
treating dermatological
tofa
Prior art date
Application number
HK12107397.0A
Other languages
English (en)
Inventor
Timothy Scott Daynard
Geoffrey C Winters
David W C Hunt
Original Assignee
Dermira Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Canada Inc filed Critical Dermira Canada Inc
Publication of HK1166786A1 publication Critical patent/HK1166786A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK12107397.0A 2009-07-08 2012-07-27 Tofa analogs useful in treating dermatological disorders or conditions HK1166786A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22404209P 2009-07-08 2009-07-08
PCT/US2010/040795 WO2011005660A1 (en) 2009-07-08 2010-07-01 Tofa analogs useful in treating dermatological disorders or conditions

Publications (1)

Publication Number Publication Date
HK1166786A1 true HK1166786A1 (en) 2012-11-09

Family

ID=43429491

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12107397.0A HK1166786A1 (en) 2009-07-08 2012-07-27 Tofa analogs useful in treating dermatological disorders or conditions
HK14102926.9A HK1189886A1 (en) 2009-07-08 2014-03-25 Tofa analogs useful in treating dermatological disorders or conditions tofa

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14102926.9A HK1189886A1 (en) 2009-07-08 2014-03-25 Tofa analogs useful in treating dermatological disorders or conditions tofa

Country Status (17)

Country Link
US (3) US8884034B2 (es)
EP (2) EP2641906B1 (es)
JP (1) JP5753844B2 (es)
KR (1) KR101722289B1 (es)
CN (2) CN105017187B (es)
AU (1) AU2010270797B2 (es)
BR (1) BR112012000254A2 (es)
CA (1) CA2766643C (es)
DK (1) DK2451796T3 (es)
ES (2) ES2421723T3 (es)
HK (2) HK1166786A1 (es)
IL (1) IL217421A0 (es)
MX (1) MX2012000435A (es)
NZ (1) NZ597375A (es)
RU (1) RU2561729C2 (es)
SG (1) SG176983A1 (es)
WO (1) WO2011005660A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) * 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US8927679B2 (en) * 2013-01-15 2015-01-06 Xerox Corporation Tuning toner gloss with bio-based stabilizers
CN105530940A (zh) 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
AU2016215228A1 (en) * 2015-02-05 2017-08-10 Dermira Inc. Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate
PL3253743T3 (pl) 2015-02-05 2020-03-31 Dermira, Inc. Syntetyczny sposób otrzymywania pochodnych kwasu 2-furanokarboksylowego
JP2019522016A (ja) * 2016-07-26 2019-08-08 デルミラ インコーポレーテッド ２−（２−エトキシ−２−オキソエチル）（メチル）アミノ−２−オキソエチル５−（テトラデシルオキシ）フラン−２−カルボキシレートの皮膚科学的製剤
WO2018170316A1 (en) * 2017-03-16 2018-09-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying myc-driven and lipogenesis-dependent neoplasms and methods of treating the same
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
CA3068623A1 (en) 2017-06-30 2019-01-03 Quixgen, Inc. Novel spirolactone compounds
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
JP6950524B2 (ja) * 2017-12-28 2021-10-13 トヨタ自動車株式会社 ハイブリッド車両の制御装置
KR20210044191A (ko) 2018-06-04 2021-04-22 아큐티스, 인크. 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
RU2678307C1 (ru) * 2018-11-13 2019-01-25 Индивидуальный предприниматель Талагаева Елена Владимировна Активная против акне добавка к парфюмерно-косметическим продуктам
CN109608415B (zh) * 2019-01-21 2020-12-01 暨南大学 噻唑甲酰胺类化合物及其合成和应用
US20200330429A1 (en) * 2019-04-22 2020-10-22 Nestlé Skin Health Sa Method of treating truncal acne with trifarotene
AU2021268977B2 (en) * 2020-05-07 2024-05-23 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high Krafft temperature anionic surfactants
CN114767665B (zh) * 2021-06-11 2023-10-10 同济大学 5-十四烷氧基-2-呋喃甲酸在制备用于治疗银屑病样皮炎的药物中的用途
DE102022201276A1 (de) 2022-02-08 2023-08-10 Beiersdorf Aktiengesellschaft Neue TOFA-Analoga, Zubereitungen zur Sebumreduktion mit einem Gehalt an solchen Analoga und die kosmetische und/oder therapeutische Verwendung solcher Analoga als wirksames Prinzip zur Sebumreduktion oder -verhinderung
DE102022201277A1 (de) 2022-02-08 2023-08-10 Beiersdorf Aktiengesellschaft Neue TOFA-Analoga, Zubereitungen zur Sebumreduktion mit einem Gehalt an solchen Analoga und die kosmetische und/oder therapeutische Verwendung solcher Analoga als wirksames Prinzip zur Sebumreduktion oder -verhinderung

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS502373B1 (es) 1969-08-18 1975-01-25
US4110351A (en) * 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
US4602099A (en) 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
US4093622A (en) 1975-05-19 1978-06-06 Zoecon Corporation Pyridine esters of cyclopropane-carboxylic acid
SU689180A1 (ru) * 1978-02-20 2006-12-27 Пермский ордена Трудового Красного Знамени государственный университет им. А.М.Горького β-(5-Бромфуроил)-β-фенилгидразиды диалкилгликолевых кислот, проявляющие противовоспалительную активность
US4935421A (en) 1981-11-12 1990-06-19 E. I. Du Pont De Nemours And Company 2-hydroxypropylamine aryl ester derivatives and pharmaceutical use
IT1140323B (it) 1981-12-09 1986-09-24 Montedison Spa Processo per la preparazione di composti carbossilati aromatici o etero-aromatici
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5151424A (en) 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
US5256625A (en) 1987-08-13 1993-10-26 Monsanto Company Safening imidazolinone herbicides
US5710100A (en) 1987-08-13 1998-01-20 Monsanto Company Safening imidazolinone herbicides
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
WO1989011535A1 (en) 1988-05-25 1989-11-30 The Queen's University Of Belfast Methylation of organic compounds
DE3829450A1 (de) 1988-08-31 1990-03-01 Hoechst Ag Nigericinderivate, verfahren zu deren herstellung, diese enthaltende mittel und verwendung derselben
DE3830509A1 (de) 1988-09-08 1990-03-22 Hoechst Ag Arzneimittel mit synergistischer antimykotischer und antiviraler wirksamkeit
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US4980371A (en) 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
DE3907784A1 (de) 1989-03-10 1990-09-13 Hoechst Ag Heteroaryl-aryl-buten- und -butanderivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
FR2648140B1 (fr) 1989-06-08 1991-05-03 Centre Nat Rech Scient Procede de preparation d'oligomeres d'heterocycles aromatiques par couplage oxydant d'oligomeres inferieurs
DE3927786A1 (de) 1989-08-23 1991-02-28 Bayer Ag Verfahren zur herstellung von aldehyden
JPH03101679A (ja) 1989-09-14 1991-04-26 Sankyo Co Ltd リゾキシン誘導体
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
EP0434517A3 (en) 1989-12-20 1991-10-16 Rhone-Poulenc Chimie Process for the preparation of mono- or poly-alkoxylated aromatic compounds
JPH03197441A (ja) 1989-12-26 1991-08-28 Sagami Chem Res Center カルボン酸類の製造方法
DE4005648A1 (de) 1990-02-22 1991-08-29 Wacker Chemie Gmbh Heteroarylenmethine und daraus hergestellte polymere
JP2916694B2 (ja) 1990-03-16 1999-07-05 コニカ株式会社 ハロゲン化銀写真感光材料及びその製造方法
JP2916700B2 (ja) 1990-07-05 1999-07-05 コニカ株式会社 ハロゲン化銀写真感光材料
EP0446899A1 (en) 1990-03-16 1991-09-18 Konica Corporation Silver halide photographic material
JPH0429969A (ja) 1990-05-28 1992-01-31 Nippon Oil & Fats Co Ltd ポリフルオロアルキル基含有ヘテロ芳香族誘導体及びその製造方法
US5034385A (en) 1990-06-26 1991-07-23 Merck & Co., Inc. 2-(heteroarylsubstituted)phenyl carbapenem antibacterial agents
IE74711B1 (en) 1990-07-27 1997-07-30 Ici Plc Fungicides
LU87821A1 (fr) 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
DE4033563A1 (de) * 1990-10-22 1992-04-23 Henkel Kgaa Antiseborrhoische zubereitungen
US5354858A (en) 1991-03-28 1994-10-11 The University Of Toledo Production and use of Diels Alder adducts of vinyl porphyrins and of compositions containing such adducts
TW279162B (es) 1991-09-26 1996-06-21 Mitsubishi Chem Corp
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE4138026A1 (de) 1991-11-19 1993-06-03 Bayer Ag Substituierte pyridin-4-carbonsaeureamide
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
FR2686162B1 (fr) 1992-01-13 1995-09-22 Commissariat Energie Atomique Modulateur spatial de lumiere a adressage optique.
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5334389A (en) 1992-10-15 1994-08-02 Duke University Antifouling coating and method for using same
US6190894B1 (en) 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
EP0640676B1 (en) 1993-08-31 1999-01-20 Canon Kabushiki Kaisha Mesomorphic compound, liquid crystal composition containing the compound, liquid crystal device using the composition, liquid crystal apparatus and display method
JP3015998B2 (ja) 1993-08-31 2000-03-06 キヤノン株式会社 液晶性化合物、それを含む液晶組成物、該液晶組成物を用いた液晶素子、液晶装置、並びに表示方法
US5569675A (en) 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
DE4412334A1 (de) 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
FR2720393B1 (fr) 1994-05-27 1996-10-25 Rhone Poulenc Chimie Réactif utile pour et procédé pour la synthèse d'ester et xanthate transestérifiable.
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
JPH0859611A (ja) 1994-08-26 1996-03-05 Nippon Soda Co Ltd ヘテロ環誘導体の製造法
US5512596A (en) 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
TW307746B (es) 1994-10-14 1997-06-11 Sumitomo Chemical Co
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
CN1195352A (zh) 1995-07-27 1998-10-07 智索公司 有机硅组化合物,液晶组合物和液晶显示仪
US6756053B2 (en) 1995-07-28 2004-06-29 Zars, Inc. Controlled heat induced rapid delivery of pharmaceuticals from skin depot
US6013666A (en) 1996-07-02 2000-01-11 Sang Sup Jew Oxirane carboxylic acid derivative and its manufacturing method
GB9620061D0 (en) 1996-09-26 1996-11-13 Secr Defence Liquid crystalline (e,e)-butadiene compounds and mixtures and devices containing such compounds
WO1998017253A1 (en) 1996-10-23 1998-04-30 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
WO2000000204A1 (en) 1997-02-14 2000-01-06 Miravant Pharmaceuticals, Inc. Indium photosensitizers for pdt
US6541472B1 (en) 1997-02-21 2003-04-01 Viropharma Incorporated Compounds, compositions and methods for preventing and treating pestivirus infection and associated diseases
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
DE19717898A1 (de) 1997-04-28 1998-10-29 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
DE19718742A1 (de) 1997-05-02 1998-11-05 Hoechst Ag Verfahren zur Herstellung von aromatischen Aldehyden durch katalytische Gasphasenhydrierung der Carbonsäuren
ES2171022T3 (es) 1997-05-07 2002-08-16 Quadra Logic Tech Inc Esteres de etilenglicol de derivados de monohidrobenzoporfirinas como agentes fotoactivos.
JPH1143792A (ja) 1997-07-23 1999-02-16 Asahi Kagaku Kogyo Co Ltd 酸洗促進剤、酸洗促進剤を含んだ酸洗液組成物およびこれを用いる酸洗方法
US5851952A (en) 1997-11-07 1998-12-22 American Cyanamid Company Herbicidal thienyloxyazines
EP1028959B1 (en) 1997-11-07 2007-06-27 Basf Aktiengesellschaft Herbicidal furanyl- and thienyloxyazines
US5869426A (en) 1997-11-07 1999-02-09 American Cyanamid Company Herbicidal 6-thienyloxypyrid-2-carboxamides
US6309561B1 (en) 1997-12-24 2001-10-30 3M Innovative Properties Company Liquid crystal compounds having a chiral fluorinated terminal portion
JP2002502852A (ja) 1998-02-09 2002-01-29 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド プロテアーゼ阻害剤、特にウロキナーゼ阻害剤としてのヘテロアリールアミジン、メチルアミジンおよびグアニジン
WO1999048371A1 (en) 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
JP4048645B2 (ja) 1998-04-10 2008-02-20 東レ株式会社 発光素子
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
US6139924A (en) 1998-11-20 2000-10-31 3M Innovative Properties Company Chiral liquid crystal compounds having a fluorinated terminal portion
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
US6183773B1 (en) 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
EA200100882A1 (ru) 1999-02-09 2002-04-25 3-Дименшенл Фамэсьютикэлс, Инк. Гетероарильные производные амидина, метиламидина и гуанидина (варианты), способ их получения, фармацевтическая композиция (варианты), способ ингибирования протеазы (варианты) и способ лечения различных заболеваний (варианты)
GB9906168D0 (en) 1999-03-17 1999-05-12 Rolic Ag Liquid crystal compounds
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
CN1073571C (zh) 1999-06-02 2001-10-24 山西大学 单核芳香族、杂环类单酰异羟肟酸二烃基锡化合物及其合成
CN1367784A (zh) 1999-06-02 2002-09-04 盐野义制药株式会社 新的取代丙烯酮衍生物的制备方法
DE19929783A1 (de) 1999-06-29 2001-01-04 Bayer Ag Substituierte 6-[4-(Oxymethyl)-phenyl]-dihydropyridazinone und ihre Verwendung
JP2002060658A (ja) 2000-08-11 2002-02-26 Fuji Photo Film Co Ltd インクジェット用インク及びインクジェット記録方法
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
US20050049242A1 (en) 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
CA2439463A1 (en) 2001-02-28 2002-09-06 Anders Hallberg Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
US7534547B2 (en) 2001-03-29 2009-05-19 Osaka Gas Company Limited Optically active compound and photosensitive resin composition
JP2002363123A (ja) 2001-03-29 2002-12-18 Kansai Research Institute 光活性化合物および感光性樹脂組成物
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
DE10125145A1 (de) 2001-05-22 2002-11-28 Gruenenthal Gmbh Substituierte C-Furan-2-yl-methylamin- und C-Thiophen-2-yl-methylamin-Derivate
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
EP1275301A1 (en) 2001-07-10 2003-01-15 Bayer CropScience S.A. Trisubstituted heterocyclic compounds and their use as fungicides
JP2003055367A (ja) 2001-08-15 2003-02-26 Kuraray Co Ltd ３−ホルミルフラン類の製造方法
JP2005194190A (ja) 2001-10-05 2005-07-21 Fumie Satou １９−ノル−ビタミンｄ誘導体の製造法
FR2831537B1 (fr) 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
AUPR970701A0 (en) 2001-12-21 2002-01-24 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
US7160921B2 (en) 2002-01-29 2007-01-09 The Gillette Company Reduction of hair growth
JP4157765B2 (ja) 2002-02-18 2008-10-01 花王株式会社 粉末油脂
US7122296B2 (en) 2002-03-05 2006-10-17 Brewer Science Inc. Lithography pattern shrink process and articles
AU2003251942A1 (en) 2002-07-17 2004-02-02 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
JP2004107271A (ja) 2002-07-22 2004-04-08 Mitsubishi Rayon Co Ltd 水溶性アルキルホスフィン誘導体とその製造方法、ホスフィン配位子錯体並びにビアリール誘導体の製造方法
JP4468810B2 (ja) 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
DE10240261A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10240262A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
TW585898B (en) 2002-12-26 2004-05-01 Ind Tech Res Inst Liquid crystal compounds with optical activities having high helical twisting power, method for preparing the same, and liquid crystal composition containing the compounds
EP2404676A1 (en) 2002-12-30 2012-01-11 The Regents of the University of California Microfluidic Control Structures
DE10300097A1 (de) 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
JP4083028B2 (ja) 2003-02-04 2008-04-30 広栄化学工業株式会社 アリールボラン化合物の製造方法
DE602004024375D1 (de) 2003-02-14 2010-01-14 Glaxo Group Ltd Carboxamidderivate
US7029729B2 (en) 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
CN100402503C (zh) 2003-03-28 2008-07-16 日产化学工业株式会社 丙烯腈化合物的制造方法
JP4715992B2 (ja) 2003-03-28 2011-07-06 日産化学工業株式会社 アクリロニトリル化合物の製造方法
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2004113258A1 (ja) 2003-06-20 2004-12-29 Shionogi & Co., Ltd. 炭素−炭素結合生成反応
ITMI20031941A1 (it) * 2003-10-09 2005-04-10 Sinclair Pharmaceuticals Ltd Composizioni farmaceutiche topiche per il trattamento delle dermatiti
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
US8119684B2 (en) 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
JP2007529422A (ja) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
US7297168B2 (en) 2004-02-02 2007-11-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
JP2007534735A (ja) 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
US7534505B2 (en) 2004-05-18 2009-05-19 The University Of Southern California Organometallic compounds for use in electroluminescent devices
US7279704B2 (en) 2004-05-18 2007-10-09 The University Of Southern California Complexes with tridentate ligands
US7445855B2 (en) 2004-05-18 2008-11-04 The University Of Southern California Cationic metal-carbene complexes
US7154114B2 (en) 2004-05-18 2006-12-26 Universal Display Corporation Cyclometallated iridium carbene complexes for use as hosts
US7491823B2 (en) 2004-05-18 2009-02-17 The University Of Southern California Luminescent compounds with carbene ligands
US7601436B2 (en) 2004-05-18 2009-10-13 The University Of Southern California Carbene metal complexes as OLED materials
US7582365B2 (en) 2005-01-10 2009-09-01 Universal Display Corporation Reversibly reducible metal complexes as electron transporting materials for OLEDs
WO2005113704A2 (en) 2004-05-18 2005-12-01 The University Of Southern California Luminescent compounds with carbene ligands
US7393599B2 (en) 2004-05-18 2008-07-01 The University Of Southern California Luminescent compounds with carbene ligands
US7655323B2 (en) 2004-05-18 2010-02-02 The University Of Southern California OLEDs utilizing macrocyclic ligand systems
US7598388B2 (en) 2004-05-18 2009-10-06 The University Of Southern California Carbene containing metal complexes as OLEDs
JP2005350527A (ja) 2004-06-09 2005-12-22 Kyowa Hakko Chemical Co Ltd 環状保護基で置換された単量体および重合体
WO2005123667A1 (en) 2004-06-22 2005-12-29 Syngenta Participations Ag Substituted bicyclooctenes and their use as herbicides
US7790935B2 (en) 2004-08-23 2010-09-07 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
MX2007004036A (es) 2004-10-08 2007-05-24 Unilever Nv Complejo de hierro para uso en el tratamiento y/o prevencion de trastornos nutricionales.
KR100784337B1 (ko) 2004-11-12 2007-12-13 한국생명공학연구원 신규한 ｏ-아실옥심 유도체, 그의 제조방법 및 이를유효성분으로 하는 심장순환계 질환의 예방 및 치료용약학 조성물
US6987207B1 (en) 2005-03-03 2006-01-17 Alan Jeffrey Ronyak Hydrocarbonaceous composition
CA2603534C (en) 2005-03-04 2014-02-04 Fan Wu Design and synthesis of novel antimicrobials
GB0505861D0 (en) 2005-03-22 2005-04-27 Univ Cardiff Methods for the synthesis of heteroaromatic compounds
ME02051B (me) 2005-04-13 2015-05-20 Astex Therapeutics Ltd Derivati hidroksibenzamida i njihova primena kao inhibitora hsp90
EP1889049A2 (en) 2005-05-25 2008-02-20 The Board of Governors for Higher Education State of Rhode Island And Providence Plantations Thermochromic and thermoflourescent pigments: enhancing color and flourescence with additives
WO2007019295A1 (en) 2005-08-05 2007-02-15 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
DE102005045132A1 (de) 2005-09-22 2007-03-29 Archimica Gmbh Verfahren zur Herstellung von 2-Arylcarbonylverbindungen, 2-Arylestern und 2-Arylnitrilen sowie ihrer heteroaromatischen Analoga
EP1787981A1 (en) 2005-11-22 2007-05-23 Bayer CropScience S.A. New N-phenethylcarboxamide derivatives
WO2007064861A2 (en) 2005-12-02 2007-06-07 Brandeis University Asymmetric friedel-crafts alkylations catalyzed by byfunctional cinchona alkaloids
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
JP4895267B2 (ja) 2006-02-21 2012-03-14 三菱レイヨン株式会社 ３，６−エポキシ−１，２，３，６−テトラヒドロフタル酸無水物誘導体の製造方法
DE602006007804D1 (de) 2006-03-31 2009-08-27 Sony Deutschland Gmbh Zusammensetzung die mindestens eine Art von Flüssigkristall enthält
EP1840188B1 (en) 2006-03-31 2011-09-07 Sony Deutschland GmbH A composition comprising at least one type of liquid crystal
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
WO2008003746A1 (en) 2006-07-06 2008-01-10 Bayer Cropscience Sa N-(4-pyridin-2-ylbutyl) carboxamide derivatives, their process of preparation and their use as fungicides
EP2054058B1 (en) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
DE102006037399A1 (de) 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
US7858126B2 (en) 2006-08-31 2010-12-28 Trinity Laboratories Inc. Derivatives of sandalwood oil and santalols for treating cold sores and herpes
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20100204317A1 (en) 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
RU2319694C1 (ru) 2007-01-19 2008-03-20 Михаил Иванович Власов Способ получения производных 3-гидроксипиридина
CL2008000512A1 (es) 2007-02-22 2008-08-29 Bayer Cropscience Sa Compuestos derivados de n-(3-fenilpropil)carboxamida; procedimiento de preparacion de dichos compuestos; composicion fungicida; y metodo para combatir de forma preventiva o curativa los hongos fitopatogenos de cultivos.
WO2008131258A2 (en) 2007-04-19 2008-10-30 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Pactamycin biosynthetic gene cluster
CN101820757A (zh) * 2007-06-01 2010-09-01 普林斯顿大学托管委员会 通过调节宿主细胞代谢途径治疗病毒感染
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2167074A2 (en) 2007-06-13 2010-03-31 NorthEastern University Antibiotic compounds
EP2003125A1 (en) 2007-06-14 2008-12-17 Total Petrochemicals Research Feluy New tridentate ligand compounds with imino furan units, method for manufacturing said compounds, and their use in the preparation of catalysts for the homopolymerisation and copolymerisation of ethylene and alpha-olefins
GB0715454D0 (en) 2007-08-08 2007-09-19 Syngenta Ltd Novel herbicides
GB0715576D0 (en) 2007-08-09 2007-09-19 Syngenta Ltd Novel herbicides
JP5365806B2 (ja) 2007-09-10 2013-12-11 日産化学工業株式会社 置換イソキサゾリン化合物及び有害生物防除剤
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
JP2010235590A (ja) 2009-03-09 2010-10-21 Nissan Chem Ind Ltd 置換イソキサゾリン化合物及び有害生物防除剤
CN101857622B (zh) 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
CN101704700B (zh) 2009-10-28 2012-04-11 东北师范大学 一种氢溴酸(溴化氢)催化芳烃的傅-克反应方法
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US8920681B2 (en) 2009-12-30 2014-12-30 Korea University Research And Business Foundation Electrically conductive polymers with enhanced conductivity
TWI532725B (zh) 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
CN102134180A (zh) 2011-01-06 2011-07-27 华东理工大学 一种呋喃衍生物的开环加氢反应新方法
AU2012205410A1 (en) 2011-01-13 2013-08-01 Qlt Inc. Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof

Also Published As

Publication number Publication date
EP2451796A1 (en) 2012-05-16
CA2766643A1 (en) 2011-01-13
CA2766643C (en) 2017-01-03
ES2540232T3 (es) 2015-07-09
HK1189886A1 (en) 2014-06-20
KR101722289B1 (ko) 2017-03-31
MX2012000435A (es) 2012-06-01
AU2010270797A1 (en) 2012-02-02
US9782382B2 (en) 2017-10-10
US20160338988A1 (en) 2016-11-24
CN102482249A (zh) 2012-05-30
EP2451796B1 (en) 2013-04-17
CN105017187B (zh) 2017-10-24
CN102482249B (zh) 2016-06-08
WO2011005660A1 (en) 2011-01-13
SG176983A1 (en) 2012-02-28
RU2012104244A (ru) 2013-09-27
US20150025069A1 (en) 2015-01-22
KR20120047234A (ko) 2012-05-11
IL217421A0 (en) 2012-02-29
JP2012532871A (ja) 2012-12-20
DK2451796T3 (da) 2013-07-29
US20120208807A1 (en) 2012-08-16
ES2421723T3 (es) 2013-09-05
EP2641906B1 (en) 2015-04-22
JP5753844B2 (ja) 2015-07-22
RU2561729C2 (ru) 2015-09-10
EP2641906A1 (en) 2013-09-25
BR112012000254A2 (pt) 2016-02-16
AU2010270797B2 (en) 2015-03-19
US8884034B2 (en) 2014-11-11
US9434718B2 (en) 2016-09-06
CN105017187A (zh) 2015-11-04
NZ597375A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
HK1189886A1 (en) Tofa analogs useful in treating dermatological disorders or conditions tofa
IL216013A (en) Dermatologic Treatment Devices
PL2320997T3 (pl) Urządzenie do poprawy działania tkanki nerwowej
IL219914A (en) In the history of 3,1-diphenylprop-2-and-1-one for the treatment of liver disorders
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
EP2512578A4 (en) DEVICES AND METHODS FOR TREATING SINUSIAN DISEASE
GB2467710B (en) Methods for treating social disorders
EP2493820A4 (en) WATER TREATMENT
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
ZA201200016B (en) Topical micro-emulsion for the treatment of rheumatic disorders
GB0800145D0 (en) Skincare treatment
IL214133A0 (en) Skin treatment
ZA201204845B (en) Agents for treating disease
EP2473171A4 (en) METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS
GB0900599D0 (en) Treatment
PL2424870T3 (pl) Środki terapeutyczne 713
GB201013898D0 (en) Well treatment
EP2410846A4 (en) GLYCOLIPIDES AS TREATMENT OF DISEASES
EP2240192A4 (en) TREATMENT OF DERMATOLOGICAL SUFFERING
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
IL207906A0 (en) Treatment for ocular-related disorders
SI2278962T1 (sl) Postopki za zdravljenje dermatoloških motenj
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
EP2376090A4 (en) SUPPRESSION OF APOE SPALTACTIVITY IN THE TREATMENT OF DISEASES RELATED TO APOE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210701